TFF Pharmaceuticals commences Phase 1 clinical trial for Voriconazole
Category: #health  By Mateen Dalal  Date: 2019-11-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

TFF Pharmaceuticals commences Phase 1 clinical trial for Voriconazole

TFF Pharmaceuticals, Inc., claims that it has initiated Voriconazole Inhalation Powder’s phase 1 clinical trial —Voriconazole’s inhaled dry powder version that is direct-to-lung and complements next-generation version. When it comes to the treatment of Invasive Pulmonary Aspergillosis (IPA), Voriconazole Inhalation Powder is regarded as the most efficacious antifungal drug.

Reportedly, the trial will start patients’ dosing this week and is slated to be undertaken at a site in Canada meant for assessing pharmacokinetic profile, tolerability and safety of Voriconazole Inhalation Powder in over 64 health subjects. The trial is anticipated to be evaluated under a Canadian CTA and US IND.

TFF Pharmaceuticals’ patented Thin Film Freezing (TFF) technology platform leverages liquid Voriconazole’s reformulation into dry powder particles with attributes perceived to be apt for inhalation delivery. For the uninitiated, the Voriconazole dry powder formulation aims at the fungal infection site in the lung and has the innate capability to be the first dry powder inhaled fungicide in the industry.

President and CEO of TFF Pharmaceuticals Glenn Mattes was all praise for TFF Pharmaceuticals that has taken a giant leap from research to product formulation to clinical trial study for Voriconazole Inhalation Powder. Mattes believes this a massive stride taken by the company and TFF technology has lived up to the expectations of innovation and viability. He went to state that TFF Pharmaceuticals will leave no stone unturned in developing new drugs with a range of commercial applications for lung condition and chronic respiratory diseases.

University of Texas Health Science Center’s Professor and Chief of Pulmonary and Critical Care, Jay Peters commented that the development of Voriconazole Inhalation Powder for the treatment of IPA is underpinned by the preclinical data produced from early animal testing with the TFF technology platform. He further asserted that the start of the first human dosing was a quantum leap towards developing an essential new drug for critically ill patients who are inflicted from IPA. Inhaled Voriconazole is believed to be instrumental in treating allergic bronchpulmonary aspergillosis (ABPA).
 

Source Credits: https://ir.tffpharma.com/news-releases/news-release-details/tff-pharmaceuticals-announces-initiation-phase-1-clinical-trial

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...